Artificial Organ Market Report 2025

The artificial organ market size has grown strongly in recent years. It will grow from $23.78 billion in 2024 to $25.93 billion in 2025 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to increasing incidence of organ failure, rising aging population, improvements in materials and biocompatibility, research and development investments, increasing awareness.

The artificial organ market size is expected to see rapid growth in the next few years. It will grow to $38.18 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to growing demand for organ transplants, expansion of indications, personalized medicine trends, increasing investment in healthcare infrastructure, greater acceptance and social awareness. Major trends in the forecast period include regulatory landscape, increasing investment, personalized medicine, integration of AI and machine learning, global collaboration.

The growing geriatric population is anticipated to drive the expansion of the artificial organ market in the coming years. The geriatric population comprises individuals aged 60 and above who require medical care. Artificial organs can significantly assist the elderly by addressing various health issues, including organ failure, thereby enhancing their quality of life. For instance, in October 2022, the World Health Organization, a Switzerland-based specialized health agency, reported that by 2030, 1 in 6 people globally will be 60 or older, and this number is expected to double to 2.1 billion by 2050. Consequently, the increasing geriatric population is set to propel the growth of the artificial organ market.

The escalating demand for organ transplants serves as another key factor driving the expansion of the artificial organ market. Organ transplantation, a vital medical procedure replacing damaged or failing organs, has increasingly relied on artificial organs to sustain life, enhance quality of life, mitigate organ shortages, prevent damage, improve compatibility, reduce rejection risks, and foster new therapeutic avenues for researchers and medical practitioners. Notably, statistics from the UK's National Health Service Blood and Transplant revealed a 27% surge in organ transplants and an 18% increase in deceased organ donors in comparison to the previous year (2021-2022). This rising demand for organ transplants underscores the pivotal role of artificial organs in meeting healthcare needs and is a significant driver propelling the artificial organ market's growth.

Major companies in the artificial organ market are increasingly pursuing a strategic partnership approach to enhance technology integration and broaden their market reach. A strategic partnership generally refers to a collaborative relationship between two or more organizations that combine their resources, expertise, and efforts to achieve shared goals or objectives. For example, in December 2022, Instalimb, a Japan-based manufacturer of 3D-printed prosthetic legs, joined forces with the renowned Jaipur Foot, an India-based company specializing in orthotics and prosthetics. This collaboration aims to leverage advanced 3D printing and machine learning (AI) technology to produce affordable, high-quality prosthetics and orthotics for patients globally. Through this partnership, Instalimb will supply its 3D-printed sockets to the Jaipur Foot Organization, which will then customize them for their patients.

Major players within the artificial organ market are prioritizing the development of innovative products, particularly leveraging AI-powered pathology solutions to drive market revenues. These solutions represent a transformative breakthrough in pathology, offering pathologists powerful tools aimed at enhancing diagnostic accuracy, operational efficiency, and ultimately, patient care. A notable example is the September 2023 launch by Aiosyn, a Netherlands-based medical software company, introducing an AI kidney suite. This innovative suite is designed to objectively quantify kidney lesion ratings, enhancing repeatability and expediting medication discovery through cutting-edge AI-powered computational pathology techniques. The platform empowers research organizations and biopharma entities to conduct in-depth analyses of kidney structures, quantifying lesions that significantly impact kidney health, courtesy of advanced deep-learning technology.

In March 2024, Nippon Express Holdings, Inc., a Japan-based logistics services provider, acquired a stake in Instalimb, Inc. for an undisclosed amount. This acquisition is intended to enhance Nippon's corporate value while tackling social issues. The investment will support Instalimb's logistics and business growth in Asian markets and potentially in emerging regions of Africa in the future. Instalimb, Inc. is a Japan-based start-up that specializes in 3D-printed prosthetics.

Major companies operating in the artificial organ market include Medtronic plc, Boston Scientific Services Private Limited., Abbott Laboratories Inc., Zimmer Biomet Holdings Inc., Ekso Bionics Holdings Inc., Cochlear Limited, Cyberonics Inc., LIVANOVA plc, NeuroPace Inc., Ossur India Private Limited, Vivani Medical Inc., St Jude Medical India Private Limited, LifeNet Health Inc., Ottobock SE & Co. KGaA, Edwards Lifesciences India Pvt. Ltd., SynCardia Systems LLC, Demant A/S, Berlin Heart GmbH, Conmed Devices Private Limited, Wright Medical Group N.V., Baxter International Inc., B. Braun Melsungen AG, ABIOMED Inc., Carmat SA, Jarvik Heart Inc., Terumo Corporation, F. Hoffmann-La Roche Ltd., Tissium SAS, Organovo Holdings Inc., Satellite Bio, HeartWare plc, Arthrex Inc., Novartis AG, Stryker Corporation.

North America was the largest region in the artificial organ market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial organ market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial organ market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Artificial organs are devices designed to be implanted or integrated into the human body, serving the purpose of replacing, duplicating, or augmenting specific functions to enable patients to return to normal life.

The primary types of artificial organs encompass artificial hearts, artificial kidneys, artificial livers, artificial pancreas, and others. For instance, an artificial heart is an implanted pump that takes over the function of damaged heart ventricles and valves. It is operated by an external mechanism called a driver. These devices are made from materials such as silicone, plastic, steel, and biomaterials, and can be fixed through implantable or external means. Various end-users benefit from artificial organs, including hospitals, ambulatory surgical centers, laboratories, diagnostic centers, research institutions, and academic institutes.

The artificial organ market research report is one of a series of new reports that provides, artificial organ market statistics, including, artificial organ industry global market size, regional shares, competitors with an artificial organ market share, detailed, artificial organ market segments, market trends and opportunities, and any further data you may need to thrive in the artificial organ industry. This artificial organ market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The artificial organ market consists of sales of orthopedic devices, neuroprostheses and neurological support, urological support, visual support systems, blood cell and tissue replacement systems, mechanical organs made of inanimate polymers, and biomechanical organs made of partially living cells and inanimate polymers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.